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ABSTRACT 49 
Helper T effector cytokines implicated in asthma modulate the contractility of human 50 
airway smooth muscle (HASM) cells. We have reported recently that a profibrotic cytokine, 51 
transforming growth factor beta 1 (TGF-β1), induces HASM cell shortening and airway hyper-52 
responsiveness (AHR). Here we assessed whether TGF-b1 affects the ability of HASM cells to 53 
relax in response to b2-agonists, a mainstay treatment for AHR in asthma. Overnight TGF-β1 54 
treatment significantly impaired isoproterenol (ISO)-induced relaxation of carbachol-stimulated 55 
isolated HASM cells. This single-cell mechanical hypo-responsiveness to ISO was corroborated 56 
by sustained increases in myosin light chain (MLC) phosphorylation. In TGF-b1 treated HASM 57 
cells, ISO evoked markedly lower levels of intracellular cAMP. These attenuated cAMP levels 58 
were, in turn, restored with pharmacological and siRNA inhibition of PDE4 and Smad3, 59 
respectively. Most strikingly, TGF-β1 selectively induced PDE4D gene expression in HASM 60 
cells in a Smad2/3-dependent manner. Together these data suggest that TGF-β1 decreases 61 
HASM cell β2-agonist relaxation responses by modulating intracellular cAMP levels via a 62 
Smad2/3-dependent mechanism. Our findings further define the mechanisms underlying β2-63 
agonist hypo-responsiveness in asthma, and suggest TGF-β1 as a potential therapeutic target to 64 
decrease asthma exacerbations in severe and treatment-resistant asthma. 65 
66 
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INTRODUCTION 70 
β2-agonist bronchodilators are a mainstay therapeutic used for acute and long-term 71 
control of asthma exacerbations. However, patients with severe asthma often respond poorly to 72 
β2-agonists, and increasing evidence demonstrates that frequent β2-agonist use leads to 73 
resistance and deterioration of asthma control (1, 2). Therefore, understanding the mechanisms 74 
mediating β2-agonist resistance is important for decreasing asthma-related morbidity and 75 
mortality. 76 
Evidence suggests a link exists between β2-adrenergic receptor (β2AR) hypo-77 
responsiveness and airway hyper-responsiveness (AHR), where increased levels of 78 
bronchoconstriction can decrease bronchodilator responsiveness (2, 3). Unsurprisingly, several 79 
cytokines modulate hyper-responsiveness and β2-agonist resistance in human airway smooth 80 
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muscle (HASM), the main regulator of bronchomotor tone (4, 5). We have previously reported 81 
that transforming growth factor β1 (TGF-β1)–a pro-fibrotic cytokine elevated in the airways of 82 
patients with asthma–augments agonist-induced contractile responses in HASM via a Smad3-83 
dependent pathway (6). However, the role of TGF-β1 in modulating β2-agonist-induced 84 
relaxation responses in HASM remains unknown. 85 
β2-agonists induce airway relaxation by binding to β2-adrenergic G-protein coupled 86 
receptors (GPCRs) on HASM cells, stimulating adenylyl cyclase (AC) enzyme activity (7). AC 87 
activation by the β2AR Gs alpha subunit elevates intracellular cyclic adenosine monophosphate 88 
(cAMP) levels, and increased cAMP leads to subsequent HASM cell relaxation by antagonizing 89 
HASM cell contractile pathways. HASM cell relaxation responses are also regulated by the 90 
action of prostaglandin E2 (PGE2), an arachidonic acid-derived mediator that exerts its effects 91 
via prostanoid EP receptors from the GPCR family (8). Stimulation of the Gs-coupled EP2 and 92 
EP4 receptor subtypes elevates intracellular cAMP levels via activation of AC, with EP4 93 
receptor stimulation selectively leading to HASM cell relaxation (9, 10). 94 
Intracellular cAMP levels in HASM cells are regulated by the balance between AC 95 
activation and cAMP-hydrolyzing phosphodiesterase (PDE) activity. While HASM cells express 96 
multiple PDE isoforms (11), functional studies have established PDE3 and PDE4 as the major 97 
cAMP hydrolyzing enzymes (12–14). PDE4, in particular, plays a pivotal role in HASM cell 98 
cAMP degradation and is more widely studied as a therapeutic target in airway disease (15). Of 99 
the four PDE4 encoding genes (16), evidence supports a critical role for PDE4D in mediating 100 
HASM cell contractile and relaxation responses (17–20). Increased PDE4D activity and 101 
expression is associated with decreased β2-agonist-induced cAMP generation in HASM from 102 
subjects with asthma (20). Mice deficient in PDE4D also exhibit a loss of responsiveness to 103 
cholinergic stimulation (10), suggesting the therapeutic potential of PDE4D inhibitors in asthma. 104 
Previous studies investigating the role of TGF-β1 in decreased β2AR responses have 105 
been purely biochemical in nature and largely limited to human tracheal smooth muscle cells and 106 
human lung embryonic fibroblasts (21, 22). As these studies were conducted in the presence of 107 
PDE inhibitors, neither study assessed the potential of TGF-β1 to modulate downstream 108 
components of the cAMP signaling pathway via PDE4. Therefore, we aimed to elucidate the 109 
mechanisms by which TGF-β1 modulates β2-agonist-induced relaxation responses in HASM 110 
cells. 111 
112 
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METHODS 113 
Human Airway Smooth Muscle (HASM) Cell Culture 114 
Human lungs from otherwise healthy, aborted transplant donors were received from the 115 
International Institute for the Advancement of Medicine (IIAM; Edison, NJ, USA) and the 116 
National Disease Research Interchange (NDRI; Philadelphia, PA, USA). HASM cells were 117 
isolated from the trachea and cultured as previously described (23). 118 
119 
Immunoblot Analysis 120 
Confluent HASM cells were serum starved overnight prior to treatment and collected as 121 
previously described (24). 122 
123 
Magnetic Twisting Cytometry (MTC) 124 
Dynamic changes in cell stiffness were measured as an indicator of the single-cell contraction 125 
and/or relaxation of isolated HASM cells as previously described (25, 26). Briefly, RGD-coated 126 
ferrimagnetic microbeads bound to the cytoskeleton were magnetized horizontally and then 127 
twisted in a vertically-aligned homogeneous magnetic field that varied sinusoidally in time (27). 128 
The ratio of specific torque to bead displacements is expressed here as the cell stiffness in units 129 
of Pascal per nm (Pa/nm).  130 
131 
Small Interfering RNA (siRNA) Transfection 132 
In vitro siRNA knockdown was performed using a reverse transfection procedure as previously 133 
described (28). HASM cells were seeded onto cell culture plates for a final siRNA concentration 134 
of 10 µM. 135 
136 
Measurement of Cyclic AMP Levels 137 
Following stimulation, cAMP levels were measured in lysed HASM cells using the Applied 138 
Biosystems cAMP-Screen® ELISA system according to manufacturer protocol. For kinetic 139 
measurement of cAMP production in live cells, HASM cells were infected with a recombinant 140 
BacMam virus expressing the cADDis cAMP sensor (Montana Molecular, Bozeman, MT) as 141 
previously described (29). Cells were stimulated with agonist then fluorescence measured at 30 142 
second intervals for 30 minutes. Data were fit to a single-site decay model using GraphPad Prism 143 
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7.0 (GraphPad Software Inc., San Diego, CA). Concentration-response curves were generated 144 
from each decay curve by multiplying the kinetic rate constant, k, with the plateau. 145 
146 
Quantitation of Phosphodiesterase (PDE) Gene Expression 147 
RNA was isolated from HASM cells using the RNeasy Mini Kit (Qiagen Sciences, Inc., 148 
Germantown, MD, USA). cDNA was generated using SuperScript™ IV First-Strand Synthesis 149 
System (Thermo Fisher Scientific, Waltham, MA, USA). Relative cDNA quantification was 150 
performed using TaqMan quantitative RT-PCR (Thermo Fisher Scientific, Waltham, MA, USA) 151 
and the DDCt method, and expression was normalized to β-actin control. 152 
153 
Statistical Analysis 154 
Unless otherwise stated, statistical analysis was conducted using GraphPad Prism software (La 155 
Jolla, CA, USA), with significance evaluated at a p-value of < 0.05. Significance was determined 156 
using Fisher’s Least Significant Differences tests or multiple t-tests with Holm-Sidak correction. 157 
For MTC experiments involving multiple lung donor cell responses, statistical analysis was 158 
conducted using mixed effect models using SAS V.9.2 (SAS Institute Inc., Cary, NC) (30). 159 
160 
Materials 161 
Compounds were purchased from Sigma Aldrich (St. Louis, MO, USA) [isoproterenol, 162 
prostaglandin E2, carbachol, perchloric acid], Selleck Chemicals (Houston, TX, USA) 163 
[roflumilast], Cayman Chemicals (Ann Arbor, MI, USA) [3-isobutyl-1-methylxanthine (IBMX)], 164 
and R&D Systems (Minneapolis, MN, USA) [TGF-β1, SB-431542]. Immunoblot antibodies 165 
were purchased from Cell Signaling Technologies (Danvers, MA, USA) [pMLC(3674S)] and 166 
EMT Millipore (Billerica, MA, USA) [MLC(MABT180)]. siRNA was purchased from Thermo 167 
Fisher Scientific (Waltham, MA, USA) [Smad3(VHS41114)] and Dharmacon (Lafayette, CO, 168 
USA) [Smad2(L-003561-00), Non-targeting Pool(D-001810-10-05)]. 169 
170 
171 
172 
173 
174 
175 
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RESULTS 176 
TGF-β1 Decreases β2-Agonist-Induced Relaxation in HASM Cells 177 
To determine the extent to which TGF-β1 mediates resistance to β2AR-induced 178 
relaxation in HASM cells, we investigated contractile outcomes in TGF-β1-pretreated HASM 179 
cells stimulated acutely with the β-agonist isoproterenol (ISO) (Fig. 1). Single-cell relaxation 180 
responses were determined using magnetic twisting cytometry (MTC), a technique that measures 181 
changes in cell stiffness as a surrogate for agonist-induced force generation (26). TGF-β1 or 182 
vehicle pretreated cells were pre-contracted to carbachol and stimulated acutely with ISO. TGF-183 
β1 significantly impaired ISO-induced single-cell relaxation in basal and carbachol-stimulated 184 
HASM cells as compared to vehicle control (Fig. 1A). No significant changes in cell stiffness 185 
were observed in non-stimulated vehicle controls for the duration of our measurements (data not 186 
shown) (25, 26). To further confirm TGF-β1’s effects on HASM cell contractile responses, we 187 
investigated the phosphorylation of MLC–an essential component of agonist-induced HASM cell 188 
contraction–following overnight TGF-β1 treatment. TGF-β1 augmented basal and agonist-189 
induced MLC phosphorylation in a similar manner to previously published literature (6). 190 
Following stimulation with ISO, MLC phosphorylation in TGF-β1-treated HASM cells remained 191 
significantly higher than that of vehicle control (Fig. 1B). Notably, the addition of the contractile 192 
agonist carbachol to TGF-β1 and ISO-treated HASM cells significantly increased MLC 193 
phosphorylation to levels above that in TGF-β1 and ISO-treated HASM cells. 194 
195 
TGF-β1 Blunts Agonist-Induced cAMP Levels 196 
To elucidate the mechanism by which TGF-β1 reduces HASM cell relaxation responses, 197 
total cAMP levels were measured in lysed TGF-β1-treated HASM cells. In TGF-β1 treated cells, 198 
ISO- and PGE2-induced cAMP levels were decreased versus that of respective control (Fig. 2A). 199 
TGF-β1 treatment did not alter forskolin-stimulated cAMP levels (Fig. 2B), suggesting that AC 200 
function was not negatively affected by TGF-b1; there were no significant differences in 201 
forskolin-evoked cAMP levels in vehicle control and TGF-b1 treated HASM cells. 202 
To further confirm these results, cAMP levels were monitored in live HASM cells 203 
pretreated with either vehicle or TGF-β1. In TGF-β1 treated cells, ISO-induced cAMP responses 204 
were 2.6-fold less potent and 1.7-fold less efficacious compared to the vehicle-treated control 205 
(Fig. 2C, E1A-B). TGF-β1 treatment appeared to decrease the potency of PGE2-stimulated 206 
cAMP responses, although this increase did not reach significance due to large variation of 207 
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PGE2 responses between donors (Fig. 2D, E1C-D). Forskolin-stimulated cAMP responses were 208 
unaffected by TGF-β1 treatment in live HASM cells (Fig. 3E, E1E-F). 209 
210 
211 
PDE Inhibition Rescues ISO-Stimulated Responses in TGF-β1-Treated HASM Cells212 
Intracellular cAMP levels are primarily reduced via hydrolysis–an effect mediated by the 213 
action of PDEs in HASM cells (31). To determine whether TGF-β1 mediates β2-agonist hypo-214 
responsiveness by modulating PDE-mediated cAMP hydrolysis, MLC phosphorylation and 215 
cAMP levels were measured in TGF-β1 and ISO-treated HASM cells in the presence or absence 216 
of the pan-PDE inhibitor IBMX (Fig. 3, E2A). 217 
MLC phosphorylation in HASM cells was increased following TGF-β1 treatment, and 218 
levels remained higher than vehicle control following ISO stimulation (Fig. 3A, left). Treatment 219 
with IBMX, however, reduced MLC phosphorylation in TGF-β1-pre-treated, ISO-stimulated 220 
HASM cells to a level similar to that of vehicle control (Fig. 3A, left). In ISO-stimulated HASM 221 
cells, MLC phosphorylation levels were increased in TGF-β1 and carbachol-treated cells above 222 
those in TGF-β1-treated cells alone (Fig. 3A, right). IBMX treatment decreased MLC 223 
phosphorylation in TGF-β1 and carbachol-treated cells to a level similar to that of vehicle control 224 
(Fig. 3A, right). 225 
We next investigated the role of PDE activity in TGF-β1-mediated decreases in ISO-226 
induced cAMP (Fig. 3B). Vehicle or TGF-β1-treated HASM cells were pre-treated with IBMX 227 
prior to ISO stimulation. IBMX pretreatment significantly elevated ISO-induced cAMP levels in 228 
TGF-β1-treated HASM cells (Fig. 3B). 229 
230 
TGF-β1 Induces PDE4D Gene Expression in a Concentration-Dependent Manner 231 
To determine the extent to which PDEs contribute to β2-agonist hypo-responsiveness in 232 
TGF-β1-treated HASM cells, we investigated the expression of HASM cell-specific PDEs in 233 
TGF-β1-treated HASM cells (Fig. E3) (29). TGF-β1 selectively increased PDE4D gene 234 
expression in a concentration-dependent manner (Fig. 4A, E3). Furthermore, inhibition of TβR-I 235 
receptor signaling with SB-431542 pretreatment blocked increased PDE4D gene expression 236 
evoked by TGF-β1. 237 
To further determine the extent to which TGF-β1 modulates PDE4D to decrease β2-238 
agonist-induced relaxation responses, cAMP accumulation, MLC phosphorylation, and cell 239 
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stiffness were measured in HASM cells treated with the PDE4 inhibitor roflumilast (Fig. 4B-D). 240 
Roflumilast pretreatment rescued blunted ISO-stimulated cAMP levels in TGF-β1-treated cells 241 
(Fig. 4B). In the presence of roflumilast, TGF-β1-induced MLC phosphorylation in ISO-242 
stimulated cells showed little increase over vehicle control (Fig. 4C, E2B). Additionally, 243 
roflumilast pretreatment decreased augmented HASM cell stiffness in TGF-β1 and ISO-244 
stimulated HASM cells (Fig. 4D). 245 
246 
TGF-β1-Decreases β2-Agonist-Induced Relaxation Responses in a Smad2/3-Dependent 247 
Manner 248 
The canonical TGF-β1 signaling pathway involves the activation of Smad2/3–249 
intracellular signaling proteins that mediate a variety of TGF-β1’s effects on HASM cell 250 
signaling in asthma (32). To determine the role of Smad proteins in TGF-β1-mediated inhibition 251 
of HASM cell relaxation responses, we investigated TGF-β1’s modulation of ISO-induced 252 
cAMP levels in Smad2/3 siRNA-transfected cells (Fig. 5). ISO-induced cAMP was significantly 253 
increased in Smad3 siRNA-transfected cells in the presence and absence of TGF-β1 treatment 254 
(Fig. 5A). TGF-β1 blunted ISO-induced cAMP levels in HASM cells transfected with non-255 
targeting and Smad2 siRNA, but had little effect on ISO-induced cAMP levels in Smad3 siRNA-256 
transfected HASM cells. 257 
To determine the role of Smad signaling in TGF-β1-mediated induction of PDE4D gene 258 
expression, PDE4D gene expression was investigated in Smad2 or Smad3 siRNA-transfected 259 
HASM cells following overnight TGF-β1 treatment (Fig. 5B). Smad2 and Smad3 knockdown 260 
reduced PDE4D gene expression induced by TGF-β1 treatment of HASM cells (Fig. 5B). 261 
262 
DISCUSSION 263 
In the present study, we demonstrate that TGF-β1 attenuates β2-agonist-induced 264 
relaxation responses in HASM cells. To date, TGF-β1 has been shown to negatively modulate β-265 
adrenergic responses in multiple cell types (21, 22, 33, 34). Here, we demonstrate that TGF-β1 266 
treatment – in the presence or absence of the contractile agonist carbachol – significantly 267 
attenuates ISO-induced HASM cell relaxation via increased cell stiffness and MLC 268 
phosphorylation (Fig. 1). Importantly – as β1 agonists have little bronchodilator effect in humans 269 
and HASM cell beta receptors are solely of the β2 subtype – this study selectively demonstrates 270 
the effects of TGF-β1 and the β-agonist ISO on β2AR-induced relaxation (35, 36). While 271 
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previous studies suggest that TGF-β1 modulates β2AR-mediated responses through a protein 272 
synthesis-dependent mechanism, the details by which this modulation occurs is not fully 273 
understood (21, 22). For the first time, we demonstrate that TGF-β1’s effects on HASM cell 274 
relaxation responses occur via a Smad2/3 pathway that upregulates the expression of PDE4D. 275 
Collectively, our findings further establish TGF-β1 as a mediator of bronchodilator resistance via 276 
modulation of downstream cAMP pathway effects. 277 
Previous studies suggest that TGF-β1 attenuates ISO-induced cAMP accumulation by 278 
negatively regulating β2AR number, protein, and gene expression (21, 22). However, our data 279 
suggest yet an additional mechanism for the attenuation of cAMP by TGF-β1. In our study, 280 
TGF-β1 blunted cAMP induced by both ISO and PGE2, a mediator that binds to the Gs/(Gi)-281 
associated prostaglandin EP2 and EP4 G protein-coupled receptors to elevate intracellular cAMP 282 
levels (Fig. 2A, 2C, 2D) (37). Little is known regarding TGF-β1’s effects on EP receptor 283 
expression in HASM, and it is unlikely that TGF-β1 blunts HASM cell cAMP by decreasing the 284 
expression of two independent Gs-coupled receptors. 285 
Interestingly, other studies suggest a role for TGF-β1 in modulating G protein function. 286 
Treatment with pertussis toxin, an irreversible Gi inhibitor, blocked TGF-β1-induced PGE2 287 
production in human lung fetal fibroblasts (38). Additionally, a report demonstrating an 288 
augmentation of cholera and pertussis toxin-induced ADP-ribosylation in TGF-β1-treated rat 289 
osteoblast-like cells suggests that TGF-β1 alters the abundance of both Gs and Gi proteins (39). 290 
TGF-β1 also modulates the expression of guanine nucleotide exchange factors (GEF) – proteins 291 
that regulate the activity of small G proteins – in various cells (40, 41). A study in murine 292 
fibroblasts suggests that TGF-β1 increases GTPase activity via a pertussis-sensitive mechanism 293 
(42). Further studies will be needed to investigate whether TGF-β1 modulates G protein 294 
expression or activity in HASM cells, and whether this potential modulation further affects 295 
HASM cell relaxation responses. However, our present results suggest that TGF-β1 – in addition 296 
to attenuating β2AR function – works downstream of the receptor level to impair ISO-stimulated 297 
cAMP levels. 298 
We used forskolin – a direct activator of AC – as a tool to further investigate TGF-β1’s 299 
downstream effects on the cAMP signaling pathway (43). In this study, TGF-β1 did not 300 
significantly alter forskolin-stimulated cAMP levels in HASM cells (Fig. 2B, 2E). Current 301 
literature suggests an unclear role for cytokines in modulating AC activity. In previous reports 302 
using human and guinea pig airway smooth muscle, TGF-β1 treatment induced little or modest 303 
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reductions in forskolin-stimulated cAMP accumulation (21, 34). Curiously, other reports 304 
demonstrate that chronic cytokine treatment sensitizes AC in HASM (44). In these studies, 305 
chronic incubation of HASM cells with the cytokine IL-1β or TNF-a caused a 2- to 3-fold 306 
increase in forskolin-stimulated cAMP (44, 45). It is posited that AC sensitization may be a 307 
feedback response to upregulate relaxation pathways in the face of cytokine-induced airway 308 
hyperresponsiveness (45). While TGF-β1 induces hyperresponsiveness in HASM cells (6), we 309 
did not find significant alteration of forskolin-stimulated cAMP in TGF-β1-treated HASM cells, 310 
(Fig. 2B). Thus, further studies will be needed to determine the effect of TGF-β1 on AC 311 
activation. 312 
As TGF-β1 did not negatively regulate AC function in HASM cells, we next investigated 313 
the role of cAMP-hydrolyzing PDE enzymes in TGF-β1’s attenuation of HASM cell relaxation 314 
responses. Previous reports suggest that TGF-β1 modulates PDE4 expression and activity. In 315 
human alveolar epithelial cells, TGF-β1 upregulated PDE4 mRNA, protein expression, and total 316 
cAMP-PDE activity (46).  TGF-β1 has also been shown to mediate fibronectin, collagen I, and 317 
connective tissue growth factor induction in bronchial rings via a PDE4D-dependent mechanism 318 
(47). In human fetal lung fibroblasts, TGF-β1-mediated collagen gel contraction, fibronectin 319 
release, and fibroblast chemotaxis was inhibited in the presence of PDE4 pharmacological 320 
inhibitors (48).  Therefore, we aimed to further investigate the role of PDE4 in the attenuation of 321 
ISO-induced cAMP by TGF-β1. 322 
We demonstrate that TGF-β1 selectively induces PDE4D gene expression in HASM 323 
cells, and that PDE4D inhibition rescues attenuated ISO-induced cAMP levels in HASM cells 324 
(Fig. E3, 4A, 4B). While roflumilast only modestly enhanced ISO-mediated decreases in TGF-325 
β1-induced MLC phosphorylation (Fig. 4C), roflumilast significantly enhanced ISO-induced, 326 
single-cell relaxation in TGF-β1-treated HASM cells (Fig. 4D). While discrepancies between 327 
biochemical and cell stiffness measurements in roflumilast-treated HASM cells are puzzling, 328 
studies suggest that both actomyosin cross-bridge cycling – regulated by MLC phosphorylation - 329 
and actin polymerization (49, 50) mediate HASM cell contractile responses. Reports demonstrate 330 
that TGF-β1 induces both MLC phosphorylation (6, 40) and actin polymerization (51, 52) in 331 
HASM cells. While the individual contributions of these pathways to HASM cell shortening 332 
remain unclear, both pathways are modulated by cAMP signaling (31, 53). Evidence suggests 333 
that PDEs shape compartmentalized cAMP signaling in the cell, where subcellular PDE 334 
localization mediates variations in cAMP-stimulated responses (16, 29, 54). As both PDE3 and 335 
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PDE4 hydrolyze cAMP in HASM, the observed discrepancy may result from the relative 336 
contribution of cAMP signaling to each pathway, driven by the spatially-mediated effects of 337 
PDE isoforms. 338 
To further determine the mechanism by which TGF-β1 attenuates ISO-induced 339 
responses, we investigated the role of the canonical TGF-β1 signaling pathway via Smad2/3 in 340 
HASM cells (Fig. 5). In non-targeting and Smad2 siRNA-transfected cells, ISO-stimulated 341 
cAMP was decreased following TGF-β1 treatment (Fig. 5A). In Smad3 siRNA-transfected cells 342 
– however – TGF-β1 had little effect on ISO-induced cAMP. Surprisingly, ISO stimulation343 
induced significantly higher cAMP levels in Smad3 siRNA-transfected cells than those observed 344 
in non-targeting siRNA-transfected cells. 345 
This increase in cAMP may indicate that Smad3 knockdown attenuates baseline TGF-β1 346 
receptor activity following the release of biologically active TGF-β1 in HASM cells (55). 347 
Alternatively, it is possible that Smad3 knockdown augments basal cAMP levels through its 348 
association with HASM cell microtubules. Smad3 has been reported to bind directly to 349 
microtubules in the absence of TGF-β1 signaling (56), and TGF-β1 has been shown to induce 350 
microtubule stability in a variety of cell types (57, 58). Therefore, impaired TGF-β1 signaling via 351 
Smad3 knockdown may exert destabilizing effects on microtubule stability. 352 
Microtubule destabilization has been correlated with impaired cAMP accumulation in 353 
multiple cell types. The microtubule assembly inhibitor colchicine has been shown to induce 354 
cAMP generation in human leukocytes in a concentration-dependent manner (59). In human 355 
leukocyte and S49 lymphoma cell studies, multiple microtubule assembly inhibitors enhanced β-356 
adrenergic and prostaglandin-stimulated cAMP accumulation in a time- and concentration-357 
dependent manner, potentially by acting on microtubules that inhibit AC activity (60, 61). 358 
However, further studies are needed to determine the significance of the interaction between 359 
Smad3 and microtubules in HASM cells, and how this interaction may affect microtubule 360 
stability and cAMP generation. 361 
In addition to modulating HASM cell cAMP levels, Smad2/3 knockdown also decreased 362 
TGF-β1-stimulated PDE4D gene expression (Fig. 5B). These findings were mirrored by a 363 
decrease in TGF-β1-stimulated PDE4D gene expression in HASM cells pre-treated with the 364 
TβR-I receptor inhibitor SB-431542 (Fig. 4A). SB-431542 is a highly selective inhibitor of the 365 
TβR-I receptor ALK5 (IC50 = 94 nM), and – to a lesser extent – the activin type I receptor 366 
ALK4, and the nodal type I receptor ALK7, which share highly-related kinase domains and 367 
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Smad2/3 proteins as substrates (62). SB-431542 selectively inhibits TGF-β1 signaling in HASM 368 
at concentrations as high as 10 µM – and exerts little effect on more divergent ALK family 369 
members that recognize bone morphogenic proteins – suggesting it to be an effective and 370 
selective inhibitor of Smad2/3 signaling in HASM (6, 62, 63). Together, these experiments 371 
suggest that TGF-β1-induced PDE4D gene expression is Smad2/3 activation-dependent. 372 
In both Smad2 and Smad3 siRNA-transfected HASM cells, PDE4D gene expression in 373 
TGF-β1-treated cells was not significantly increased over vehicle control (Fig. 5B). These results 374 
are surprising given that Smad2 and Smad3 exert differential effects on β2-agonist-induced 375 
cAMP in TGF-β1-treated cells (Fig. 5A). However, these results support previous studies 376 
demonstrating that Smad2 and Smad3 can exert differential effects on cell function (6, 64, 65). It 377 
is possible that Smad3 selectively modulates PDE4D activity, while Smad2/3 mediate induction 378 
of PDE4D expression by TGF-β1. However, more studies will be needed to assess the potential 379 
role of Smad2/3 in PDE4D activation. Nonetheless, our collective findings demonstrate a role for 380 
TGF-β1 and Smad2/3 signaling in decreased HASM cell relaxation responses. 381 
Due to the breadth and complexity of TGF-β1 signaling, there may be additional 382 
pathways by which TGF-β1 attenuates HASM cell cAMP levels that we did not investigate in 383 
this study. Other cytokines that attenuate HASM cell relaxation responses – such as IL-1β  – 384 
attenuate ISO-induced cAMP via COX-2 induction and prostanoid release (66, 67). As TGF-β1 385 
induces COX-2 expression in HASM cells (68), it is possible that prostanoid induction 386 
contributes to TGF-β1’s impairment of relaxation responses. Further studies will be needed to 387 
determine the contribution of potential TGF-β1 signaling pathways in HASM cell relaxation 388 
responses. 389 
In conclusion, our study further establishes TGF-β1 as a mediator of bronchodilator 390 
resistance in asthma via a Smad3-dependent pathway (Fig. 6). In light of our previous work on 391 
TGF-β1-induced hyperresponsiveness in HASM, these results further suggest TGF-β1 to be a 392 
promising therapeutic target to increase bronchodilator sensitivity and attenuate airway 393 
obstruction in asthma. 394 
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FIGURE LEGENDS 621 
622 
Figure 1. TGF-β1 Decreases β2-Agonist-Induced Relaxation in HASM Cells. A) Single-cell 623 
relaxation of isoproterenol (ISO)-stimulated HASM cells in the presence or absence of TGF-β1 624 
(10 ng/mL, 18 h) (N= 3 donors ± SEM). HASM cells were contracted with carbachol (CCh) for 5 625 
min and subsequently relaxed with isoproterenol. CCh-stimulated stiffness was measured for the 626 
first 0-60 s, and changes in cell stiffness in response to ISO were measured continuously up to 627 
the indicated time (60-300 s). For each cell, stiffness was normalized to CCh-stimulated stiffness 628 
before ISO stimulation. B) Phosphorylated MLC following TGF-β1 (10 ng/mL, 18 h), CCh (20 629 
μM; bottom left), and/or isoproterenol (ISO, 1 μM; bottom right) treatment (N=4-7 ± SEM). 630 
Representative immunoblot of seven separate experiments. *P < 0.05 631 
632 
Figure 2. TGF-β1 Blunts Agonist-Induced cAMP Levels. A) HASM cells were pre-treated 633 
with TGF-β1 (10 ng/mL) overnight and acutely stimulated with ISO (1 μM, 5 min) (N=7 ±634 
SEM; ISO 1 μM: 3684.2 ±  1170.0 pmol/well), PGE2 (100 nM; 5 min) (N=4 donors ± SEM; 635 
PGE2: 40270.4 ±  25537.2 pmol/well), or B) Forskolin (10 μM; 15 min) (N=3 donors ± SEM; 636 
FSK 10 μM: 7192.4 pmol/well ±  3244.3) prior to lysis for cAMP level determination. C) Live 637 
HASM cells were pre-treated with TGF-β1 (10 ng/mL) overnight then acutely stimulated with 638 
various concentrations of this indicated drug and cAMP levels monitored using cADDis.  639 
Isoproterenol (vehicle logEC50 -9.25 ± 0.258, Emax 0.0052 ± 0.00035; TGF-β1 logEC50 -8.83 ± 640 
0.433, Emax 0.0031 ± 0.00038). D) PGE2 (vehicle logEC50 -9.08 ± 1.798, Emax 0.0026 ± 0.00065; 641 
TGF-β1 logEC50 -8.37 ± 0.647, Emax 0.0021 ± 0.00048). E) Forskolin (vehicle logEC50 -5.40 ± 642 
1.547, Emax 0.010 ± 0.0012; TGF-β1 logEC50 -5.44 ± 2.31, Emax 0.0074 ± 0.0132). Data is 643 
expressed as mean ± SEM of N=5 donors. *P < 0.05 **P < 0.01; ***P < 0.001. 644 
645 
Figure 3. PDE Inhibition Rescues ISO-Stimulated Responses in TGF-β1-Treated HASM 646 
Cells. A) MLC phosphorylation in HASM cells pre-treated with vehicle or TGF-β1 (10 ng/mL; 647 
18h) and/or IBMX (500 μM, 30 min) prior to stimulation with CCh (20 μM; 12 min) and/or ISO 648 
(1 μM, 10 min) (N=4 ± SEM; Max: 23.2 fold change over vehicle ± 9.4). B) cAMP levels in 649 
TGF-β1 (10 ng/mL; 18h)-treated HASM cells pre-treated with vehicle (N=7± SEM; ISO 1 μM: 650 
3684.2 ± 1170.0 pmol/well) or IBMX (500 μM, 30 min) (N=6± SEM; IBMX 1 μM ISO: 651 
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11927.4 ±  1599.3 pmol/well) prior to ISO (1 μM, 5 min) stimulation. N=4 donors ± SEM. *P < 652 
0.05 653 
654 
Figure 4. TGF-β1 Induces PDE4D Gene Expression in a Concentration-Dependent 655 
Manner. A) PDE4D gene expression in TGF-β1-treated (10 ng/ml; 18 h) HASM cells in the 656 
presence or absence of SB-431542 (5 μM; 1 h pretreatment) (N=3 donors ± SEM). B) cAMP 657 
levels in ISO-stimulated HASM cells treated with TGF-β1 (10 ng/mL; 18h) in the presence or 658 
absence of roflumilast (RF; 10 μM, 30 min) pretreatment (N=6 ± SEM; ISO μM: 1281.1 ±  406.6 659 
pmol/well). C) MLC phosphorylation in TGF-β1 (10 ng/ml; 18 h)-treated HASM cells in the 660 
presence of roflumilast (RF; 10 μM, 30 min), CCh (20 μM, 12 min) and/or ISO (1 μM, 10 min) 661 
stimulation (N=6 donors ± SEM).  D) Single-cell relaxation of TGF-β1 (10 ng/ml 18 h)-treated 662 
HASM cells in the presence or absence of roflumilast (RF; 10 μM, 30 min) (N=1 donor; N=223 663 
± SEM). *P < 0.05; relative to control unless otherwise shown. 664 
665 
Figure 5. TGF-β1-Decreases β2-Agonist-Induced Relaxation Responses in a Smad2/3-666 
Dependent Manner. A) Top: cAMP levels in non-targeting (NT) or Smad2/3 siRNA-transfected 667 
HASM cells pre-treated with TGF-β1 (10 ng/mL, 18 h) and stimulated with CCh (20 μM; 10 668 
min) and/or ISO (1 μM, 5 min) (N=4 donors ± SEM; Max: 15397.2 ± 3010.4 pmol/well). 669 
Bottom: Representative immunoblot of total Smad3 (left, 16% of NT siRNA control ± 15%, 670 
N=3) and total Smad2 (right, 10.7% of NT siRNA control ± 22.7%, N=3) protein expression in 671 
Smad2/3 siRNA transfected HASM cells. B) Top: PDE4D gene expression in non-targeting 672 
(NT)- or Smad2/3 siRNA-transfected HASM cells pre-treated with SB-431542 (5 μM, 30 min) 673 
prior to TGF-β1 (10 ng/mL) overnight treatment (N=3-4 donors ± SEM). Bottom: Representative 674 
immunoblot of total Smad3 (left, 20.3% of NT siRNA control ± 4.2%, N=3) and total Smad2 675 
(right, 38.1% of NT siRNA control ± 23.4%, N=3) in Smad2/3 siRNA transfected HASM cells. 676 
*P < 0.05677 
678 
Figure 6. Proposed Role of TGF-β1 in HASM Cell Contractile Responses in Asthma. TGF-679 
β1 signaling augments basal and HASM cell shortening through a Smad3, ROCK-dependent 680 
pathway as previously described (6). In addition to modulating HASM cell contractile responses, 681 
Smad2/3 activation increases PDE4D gene expression, leading to increased cAMP hydrolysis 682 
and blunted HASM cell relaxation responses. TGF-β1, transforming growth factor beta 1; TβR-683 
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I/II, TGF-β receptor I/II; ROCK, rho-associated protein kinase; RhoA, Ras homolog gene family, 684 
member A; MLCP, myosin light-chain phosphatase; MLCK, myosin light chain kinase; MLC20, 685 
20-kDa myosin light chain 20; cAMP, cyclic adenosine monophosphate; 5’AMP, 5’ adenosine686 
monophosphate; PDE4D, phosphodiesterase 4D. 687 
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Supplementary Methods 
Human Airway Smooth Muscle (HASM) Cell Culture 
Human lungs from otherwise healthy, aborted transplant donors were received from the 
International Institute for the Advancement of Medicine (IIAM; Edison, NJ, USA) and the 
National Disease Research Interchange (NDRI; Philadelphia, PA, USA). All HASM cell cultures 
were derived from non-smokers with no prior documented history of respiratory disease (for 
additional data, see Supplemental Fig. 4). HASM cells were isolated from the trachea and cultured 
as previously described (1). HASM cells were used solely at subculture passages 1-4 due to strong 
native contractile protein expression (2).  HASM cells were serum starved 24 h prior to treatment. 
Immunoblot Analysis 
Confluent HASM cells were serum starved overnight prior to treatment and collected as previously 
described (3). Briefly, HASM cells were serum-starved for 24 h prior to treatment, and perchloric 
acid was added to the cell media for a final concentration of 0.1%. Cells were then scraped, 
pelleted, and resuspended in RIPA lysis and sample buffer. Samples were then heated, subjected 
to SDS-PAGE, and then transferred to nitrocellulose membranes as previously described (3, 4). 
Phosphorylation of MLC was normalized to total MLC protein. Immunoblots are single 
experiments representative of at least three biological replicates. 
Magnetic Twisting Cytometry (MTC) 
Dynamic changes in cell stiffness were measured as an indicator of the single-cell contraction 
and/or relaxation of isolated HASM cells as previously described (5, 6). Briefly, RGD-coated 
ferrimagnetic microbeads (4.5 µm in diameter) bound to the cytoskeleton through cell surface 
integrin receptors were magnetized horizontally and then twisted in a vertically aligned 
homogeneous magnetic field that was varying sinusoidally in time.  This sinusoidal twisting 
magnetic field caused both a rotation and a pivoting displacement of the bead: as the bead moves, 
the cell develops internal stresses which in turn resist bead motions (7).   
To assess changes in cell stiffness, HASM cells were pre-contracted with carbachol (CCh) for 5 
min and subsequently relaxed with isoproterenol. CCh-stimulated stiffness was measured for the 
first 0-60 s, and changes in cell stiffness in response to ISO were measured continuously up to the 
indicated time (60-300 s). For each cell, stiffness was normalized to CCh-stimulated stiffness 
before ISO stimulation. Lateral bead displacements in response to the resulting oscillatory torque 
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were detected with a spatial resolution of ~5 nm, and the ratio of specific torque to bead 
displacements was computed and expressed here as the cell stiffness in units of Pascal per nm 
(Pa/nm). Studies were conducted in the absence of a non-stimulated control as we have previously 
determined that a non-stimulated vehicle control does not appreciably change cell stiffness for the 
duration of our measurements (5, 6).  
Small Interfering RNA (siRNA) Transfection 
In vitro siRNA knockdown was performed using a reverse transfection procedure as previously 
described (8). Ham’s F-12 media, siRNA, and HiPerFect Transfection Reagent (Qiagen #301705) 
were combined and incubated for 20 min at room temperature. Confluent HASM cells were 
trypsinized, pelleted, and resuspended in Ham’s F-12 media. The HASM cell suspension was 
incubated with the siRNA mixture for 15 min prior to seeding on cell culture plates. After 6 h, 
complete cell culture media (Ham’s F-12 medium supplemented with 100 U mL-1 penicillin, 0.1 
mg mL-1, streptomycin, 2.5 mg mL-1 amphotericin B and 10% FBS) was added to the seeded 
cells in a 1:1 ratio for a final siRNA concentration of 10 µM. Media was replaced with complete 
media after 18 h, and cells were serum-starved and treated with TGF-β1 24 h prior to collection. 
Cells were collected 72 h post-transfection. Only experiments that successfully reduced target 
protein expression by >40% were included in the analysis. 
Measurement of Cyclic AMP Levels 
Following stimulation, cAMP levels were measured in lysed HASM cells using the Applied 
Biosystems cAMP-Screen® ELISA system according to manufacturer protocol. For kinetic 
measurement of cAMP production in live cells, HASM cells were infected with a recombinant 
BacMam virus expressing the cADDis cAMP sensor (Montana Molecular, Bozeman, MT) as 
previously described (9). Cells were stimulated with agonist then fluorescence measured at 30 
second intervals for 30 minutes. Data were fit to a single site decay model using GraphPad Prism 
7.0 (GraphPad Software Inc., San Diego, CA). Concentration-response curves were generated 
from each decay curve by multiplying the kinetic rate constant, k, with the plateau. 
Quantitation of Phosphodiesterase (PDE) Gene Expression 
RNA was isolated from HASM cells using the RNeasy Mini Kit (Qiagen Sciences, Inc., 
Germantown, MD, USA). cDNA was generated using SuperScript™ IV First-Strand Synthesis 
For Review Only
System (Thermo Fisher Scientific, Waltham, MA, USA). Relative cDNA quantification for PDE 
isoforms was performed using TaqMan quantitative RT-PCR (Thermo Fisher Scientific, Waltham, 
MA, USA) and the DDCt method. Gene expression assays were from Thermo Fisher and validated 
against –RT controls and known non-expressing cell lines (HEK293,	HFL1,	PC12,	COS7). 
Statistical Analysis 
Unless otherwise stated, statistical analysis was conducted using GraphPad Prism software (La 
Jolla, CA, USA), with significance evaluated at a p-value of < 0.05. Significance was determined 
using Fisher’s Least Significant Differences tests or multiple t-tests with Holm-Sidak correction. 
For MTC experiments involving multiple lung donor cell responses, statistical analysis was 
conducted using mixed effect models using SAS V.9.2 (SAS Institute Inc., Cary, NC) (10). 
Materials 
Compounds were purchased from Sigma Aldrich (St. Louis, MO, USA) [isoproterenol, 
prostaglandin E2, carbachol, perchloric acid], Selleck Chemicals (Houston, TX, USA) 
[roflumilast], Cayman Chemicals (Ann Arbor, MI, USA) [3-isobutyl-1-methylxanthine (IBMX)], 
and R&D Systems (Minneapolis, MN, USA) [TGF-β1, SB-431542]. Immunoblot antibodies were 
purchased from Cell Signaling Technologies (Danvers, MA, USA) [pMLC(3674S)] and EMT 
Millipore (Billerica, MA, USA) [MLC(MABT180)]. siRNA was purchased from Thermo Fisher 
Scientific (Waltham, MA, USA) [Smad3(VHS41114)] and Dharmacon (Lafayette, CO, USA) 
[Smad2(L-003561-00), Non-targeting Pool(D-001810-10-05)]. 
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DONOR CHARACTERISTICS
Sex, M/F 16/10
Age, yr 30.54 (13.82)
Race, C/B/H/NA 17/5/3/1
BMI, kg/m2 28.96 (8.42)
Data are means (SD); n = 26 donors. M, male; F, female; C, Caucasian; 
B, Black; H, Hispanic; NA, Native American; BMI, body mass index
